{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:16:20Z","timestamp":1791278180775,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.ygyno.2009.05.042","type":"journal-article","created":{"date-parts":[[2009,7,5]],"date-time":"2009-07-05T04:15:27Z","timestamp":1246767327000},"page":"90-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Activity of 2 methoxyestradiol (Panzem\u00ae NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial"],"prefix":"10.1016","volume":"115","author":[{"given":"Daniela","family":"Matei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Breen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Check","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Sidor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2009.05.042_bb0005","first-page":"7","article-title":"Cancer statistics, 2000","volume":"50","author":"Greenlee","year":"2000","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0010","series-title":"Cancer, Principles and Practice of Oncology","first-page":"1502","article-title":"Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma","volume":"vol. 1","author":"Ozols","year":"1997"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0015","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0020","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpres- sion of HER2: a phase II trial of the Gynecologic Oncology Group","volume":"21","author":"Bookman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0092-8674(91)90642-C","article-title":"Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation","volume":"64","author":"Liotta","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/edrv.18.1.0287","article-title":"The biology of vascular endothelial growth factor","author":"Ferrara","year":"1997","journal-title":"Endocrinol Rev"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0040","first-page":"549","article-title":"Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma","volume":"23","author":"Gadducci","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0045","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0090-8258(03)00367-6","article-title":"The influence of microvessel density on ovarian carcinogenesis","volume":"90","author":"Stone","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0050","first-page":"1401","article-title":"Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome","volume":"19","author":"Gadducci","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0055","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/BF02893464","article-title":"Isolation and purification of vascular endothelial growth factor (VEGF) from ascitic fluid of ovarian cancer patients","volume":"10","author":"Ghosh","year":"2004","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0060","first-page":"1973","article-title":"Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer","volume":"24","author":"Li","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0065","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/bjc.1998.311","article-title":"Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer","volume":"77","author":"Obermair","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0070","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ygyno.2003.08.022","article-title":"VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer","volume":"91","author":"Wong","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0075","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000065066","article-title":"Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer","volume":"62","author":"Hata","year":"2002","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0080","first-page":"3403","article-title":"Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothe- lium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0046-8177(98)90226-X","article-title":"MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts","volume":"29","author":"Afzal","year":"1998","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0090","first-page":"2799","article-title":"Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications","volume":"15","author":"Garzetti","year":"1995","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0095","series-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study Proc of American Soc of Clinical Oncology","author":"Burger","year":"2005"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0100","series-title":"Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: a California Cancer Consortium Trial Proc of American Soc of Clinical Oncology","author":"Garcia","year":"2005"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0105","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0026-895X(24)12200-6","article-title":"2-Methoxyestradiol and analogs as novel antiproliferative agents: analysis of three-dimensional quantitative structure-activity relationships for DNA synthesis inhibition and estrogen receptor binding","volume":"61","author":"Hughes","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/368237a0","article-title":"The endogenous oestrogen metabolite 2-methoxyoestradiol inhi- bits angiogenesis and suppresses tumour growth","volume":"368","author":"Fotsis","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0115","doi-asserted-by":"crossref","first-page":"534","DOI":"10.2353\/ajpath.2008.061244","article-title":"2- methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis","volume":"172","author":"Becker","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0120","doi-asserted-by":"crossref","first-page":"8665","DOI":"10.1158\/1078-0432.CCR-04-1393","article-title":"2- methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma","volume":"10","author":"Ricker","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0125","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1021\/jm00012a003","article-title":"Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymeriza- tion by binding to the colchicine binding site","volume":"38","author":"Cushman","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0130","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1158\/1535-7163.MCT-06-0113","article-title":"2-Methoxyes- tradiol suppresses microtubule dynamics and arrests mitosis without depolyme- rizing microtubules","volume":"5","author":"Kamath","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0135","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/carcin\/bgg058","article-title":"Roles of p38- and c-jun NH2- terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induc- tion and apoptosis","volume":"24","author":"Shimada","year":"2003","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mc.1046","article-title":"2-methoxyestradiol blocks cell-cycle progression at G(2)\/M phase and inhibits growth of human prostate cancer cells","volume":"31","author":"Kumar","year":"2001","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2005.01.018","article-title":"2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells","volume":"231","author":"Perez-Stable","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0150","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/1097-0142(20000901)89:5<983::AID-CNCR7>3.0.CO;2-G","article-title":"Comparison of 2-methoxyestradiol- induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species","volume":"89","author":"Lin","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0155","first-page":"468","article-title":"2- methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway","volume":"63","author":"LaVallee","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1158\/0008-5472.387.65.2","article-title":"Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer","volume":"65","author":"Han","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0165","first-page":"493","article-title":"Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines","volume":"5","author":"Schumacher","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0170","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.1158\/1078-0432.CCR-05-0440","article-title":"A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacoki- netics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer","volume":"11","author":"Sweeney","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0175","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/cbt.5.1.2349","article-title":"Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors","volume":"5","author":"Dahut","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0180","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10637-006-9008-5","article-title":"Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer","volume":"25","author":"James","year":"2007","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0185","unstructured":"Fogler WE, VK, Swartz GM, Plum SM, Strawn SJ, LaVallee TM, et al. The antitumor activity of 2-methoxyestradiol is maximized by maintaining a threshold concentration over a 24-hour dosing interval. Proceedings of the AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics, B180, page 173."},{"key":"10.1016\/j.ygyno.2009.05.042_bb0190","article-title":"Fogler Effect of route of administration, dose, and schedule on the anti-tumor activity of Panzem\u00ae NCD in a murine orthotopic lung cancer model","volume":"703","author":"Kirk","year":"2005"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0195","first-page":"129","article-title":"Wilding G Phase Ib trial of 2ME2 administered as a nannocrystal dispersion (NCD) in patients with advanced cancer","volume":"B14","author":"Liu","year":"2005"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0200","first-page":"157","article-title":"A single center, open label, dose escalation, safety and pharmacokinetic study of 2 methoxi-nannocrystal colloidal dispersion administered orally to patients with advanced cancer","volume":"B121","author":"Sweeney","year":"2005"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0205","first-page":"81","article-title":"Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol","volume":"57","author":"Klauber","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0210","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0215","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0220","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1368-7646(02)00003-1","article-title":"Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase\/Akt pathway","volume":"5","author":"Cheng","year":"2002","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0225","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1535-6108(03)00077-1","article-title":"2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF","volume":"3","author":"Mabjeesh","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0230","first-page":"81","article-title":"Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol","volume":"57","author":"Klauber","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0235","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0960-0760(02)00268-6","article-title":"Effect of 2-methoxyestradiol on the growth of methyl-nitroso-urea (MNU)-induced rat mammary carcinoma","volume":"84","author":"Lippert","year":"2003","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0240","first-page":"2641","article-title":"2-methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis: possible role of vascular endothelial growth factor","volume":"20","author":"Banerjeei","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0245","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-05-0462","article-title":"Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study","volume":"11","author":"Schilder","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0250","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-006-0343-1","article-title":"Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site","volume":"60","author":"Seve","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0255","first-page":"E25","article-title":"Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy","volume":"92","author":"Dumontet","year":"2005","journal-title":"Bull Cancer"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0260","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.1999.17.3.1061","article-title":"Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death","volume":"17","author":"Dumontet","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0265","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1158\/1535-7163.MCT-05-0244","article-title":"Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non- small cell lung cancer receiving paclitaxel","volume":"4","author":"Seve","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0270","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-05-0285","article-title":"Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy","volume":"11","author":"Seve","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0275","doi-asserted-by":"crossref","first-page":"9406","DOI":"10.1158\/0008-5472.CAN-05-0088","article-title":"beta- Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA- MB-435 cancer cells","volume":"65","author":"Gokmen-Polar","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0280","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1158\/1535-7163.MCT-08-0442","article-title":"Class I {beta}-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions","volume":"7","author":"Liaw","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0285","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/1471-2407-8-206","article-title":"ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo","volume":"8","author":"Moser","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0290","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.1021\/ac800848j","article-title":"On-chip, cell-based microarray immunofluorescence assay for high-throughput analysis of target proteins","volume":"80","author":"Fernandes","year":"2008","journal-title":"Anal Chem"},{"key":"10.1016\/j.ygyno.2009.05.042_bb0295","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1535-7163.MCT-08-0107","article-title":"Significant antitumor activity in vivo following treatment with the microtubule agent ENMD- 1198","volume":"7","author":"LaVallee","year":"2008","journal-title":"Mol Cancer Ther"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809003813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809003813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:29:00Z","timestamp":1758770940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809003813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0090825809003813"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.05.042","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of 2 methoxyestradiol (Panzem\u00ae NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.05.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}